Jump to content
SCLERO.ORG
Sclero Forums

Joelf

Administrators
  • Content Count

    5,637
  • Joined

  • Last visited

1 Follower

About Joelf

  • Rank
    Star Ruby Member

Profile Information

  • Location
    West Sussex

Recent Profile Visitors

7,784 profile views
  1. Interleukin-17A biomarker as a predictor for detection of early axial spondyloarthritis (SpA) changes in patients with psoriasis. Our study can imply that IL-17A is a valuable, useful and low–cost biomarker in detecting early axial SpA changes in asymptomatic and nonradiographic axial SpA psoriatic patients. PubMed, Int J rheumatologist Dis, 10/05/2020. (Also see Interleukins and Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Fatigue and its relationship with disease-related factors in patients with systemic sclerosis (SSc): a cross-sectional study. We recommend multidisciplinary approaches to evaluate and improve these parameters in the treatment of fatigue from the early period in SSc patients. PubMed, Turk J Med Sci, 09/15/2020. (Also see Fatigue) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Hi Lisa, Welcome to these forums. I'm sorry to hear that you've been suffering for so long with such a plethora of different symptoms. Please note that I have no medical training and the symptoms you describe could relate to any number of health issues and not necessarily scleroderma or any connective tissue disease. The best person to advise you is your doctor/ endocrinologist when you have your next appointment and judging by the number of different symptoms you describe, it may be necessary for you to have further referrals to other specialists.
  4. 5 Things to Know About a COVID Vaccine: It Won’t Be a ‘Magic Wand ’. Even after a vaccine wins Food and Drug Administration approval, there would be a long wait before it’s time to declare victory over the virus. Kaiser Health News, 10/05/2020. (Also see Vaccinations) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. Blood–brain barrier (BBB) leakage in systemic lupus erythematosus (SLE) is associated with gray matter loss and cognitive impairment. Our findings provide evidence for a link between extensive BBB leakage and changes in both brain structure and cognitive function in patients with SLE. PubMed, Ann rheumatologist Dis, 10/01/2020. (Also see Symptoms and Complications of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Undifferentiated connective tissue disease at risk for systemic sclerosis (SSC): Which patients might be labeled prescleroderma? Predicting at onset which patients with Raynaud’s phenomenon are going to develop SSc over time has long been a research objective and still is an unaccomplished task. PubMed, Autoimmun Rev, 2020 Sep 14;102659. (Also see Undifferentiated Connective Tissue Disease) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  7. What Does ‘Negative’ on a Coronavirus Test Really Mean? It’s thus very possible to be antigen negative but P.C.R. positive, while still harboring the virus in the body. New York Times, 10/15/2020. This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. Prevalence of antimitochondrial antibodies in subacute cutaneous lupus erythematosus (SCLE). A high prevalence of AMA-M2 was found in patients with SCLE. PubMed, Int J Dermatol, 10/05/2020. (Also see Antibodies in Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  9. Hi Tony, I've never had TPE, so can't advise you from my own experience. I'm in the UK and frankly the chance of obtaining that particular treatment is negligible. From what I can gather, it's quite a invasive procedure and not something to be tried unless it's a fairly last resort. Your scleroderma expert is really the best person to advise you of any treatment needed. Kind regards,
  10. Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A scleroderma patient-centered intervention network (SPIN) cohort study. Anxiety symptoms, but not depression symptoms, increased dramatically during COVID-19 among people with a pre-existing medical condition. Journal of Psychosomatic Research, 10/03/2020. (Also see Anxiety and Attitude) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  11. As dentists reopened in late spring, very few got Covid-19, survey finds. Early on in the pandemic, it was widely believed that dentists would be at high risk of contracting Covid-19. NBC Health News, 10/15/2020. (Also see Dental Involvement) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  12. Hi Tony, We do have a medical page on Therapeutic Plasma Exchange here, which I hope you'll find helpful and informative. Kind regards,
  13. Hi Tony, We do have a lot of information about scleroderma in our medical pages here. Kind regards,
  14. Residual Disease Activity (RDA) and Associated Factors in Psoriatic Arthritis (PsA). RDA can be recognized in patients with PsA and very low disease activity seems to be the most stringent composite index to identify patients in the absence of RDA. PubMed, J Rheumatol, 2020 Oct 1;47(10):1490-1495. (Also see Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  15. TL1A Promotes Lung Tissue Fibrosis and Airway Remodeling. Reagents that disrupt the interaction of TL1A with DR3 then have the potential to prevent deregulated tissue cell activity in lung diseases that involve fibrosis and remodeling. PubMed, J Immunol, 2020 Sep 21;ji2000665. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×
×
  • Create New...